Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	At Market Equity Offering Programs	Common Stock	Common Stock At Market Equity Offering Programs	Common Stock 2020 ATM	Additional Paid-in Capital	Additional Paid-in Capital At Market Equity Offering Programs	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2020			68,841,288
Balance at beginning of period at Dec. 31, 2020	$ 228,087		$ 7			$ 508,499		$ (280,419)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)			148,472
Exercise of stock options	764					764
Vesting of restricted stock units, net of employee tax obligations (in shares)			61,678
Vesting of restricted stock units, net of employee tax obligations	(259)					(259)
Stock-based compensation expense	4,039					4,039
Net (loss) income	(34,693)							(34,693)
Balance at end of period (in shares) at Mar. 31, 2021			69,051,438
Balance at end of period at Mar. 31, 2021	197,938		$ 7			513,043		(315,112)
Balance at beginning of period (in shares) at Dec. 31, 2021			73,709,056
Balance at beginning of period at Dec. 31, 2021	$ 121,741		$ 7			572,213		(450,479)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under public offering, net of issuance costs (in shares)				13,169,903	11,740,210
Issuance of common stock under public offering, net of issuance costs		$ 60,462		$ 2			$ 60,460
Exercise of stock options (in shares)	26,951		26,951
Exercise of stock options	$ 96					96
Vesting of restricted stock units, net of employee tax obligations (in shares)			167,174
Vesting of restricted stock units, net of employee tax obligations	0					0
Stock-based compensation expense	5,485					5,485
Net (loss) income	(47,258)							(47,258)
Balance at end of period (in shares) at Mar. 31, 2022			87,073,084
Balance at end of period at Mar. 31, 2022	$ 140,526		$ 9			$ 638,254		$ (497,737)
Increase (Decrease) in Stockholders' Equity
Stock issuance costs		$ 1,322